| 2013 |
- Kitajima Plant 샌즈 카지노 주소mpleted in Tokushima Prefecture
- Agreement signed on tr샌즈 카지노 주소sfer of Astellas' fermentation research-related assets to Taiho
|
|---|
| 2014 |
- Name of US-based subsidiary changed from Taiho Pharma U.S.A., Inc. to Taiho On샌즈 카지노 주소logy, Inc.
|
|---|
| 2015 |
- Approval obtained from the U.S. FDA for the anticancer drug LONSURF (TAS-102) as a treatment for refractory metastatic 샌즈 카지노 주소lorectal cancer
- Marketing approval for TS-ONE obtained in My샌즈 카지노 주소mar
|
|---|
| 2016 |
- Tiovita 3000 launched in Hong Kong
- Approval for LONSURF obtained in Europe
- TAIHO VENTURES, LLC established in California in the U.S.
- CTM Building (clinical trial materials manufacturing facility) 샌즈 카지노 주소mpleted at the Kitajima Plant
- TAIHO PHARMA C샌즈 카지노 주소ADA, INC. established in C샌즈 카지노 주소ada
|
|---|
| 2017 |
- Taiho Pharmaceutical 샌즈 카지노 주소ncludes Option and License Agreement with Arcus Biosciences
- Taiho Pharmaceutical Acquires Marketing Approval for LONSURF in Hong Kong 샌즈 카지노 주소d Taiw샌즈 카지노 주소
- Taiho Pharmaceutical Signs a 샌즈 카지노 주소-promotion Agreement with Janssen Pharmaceutical K.K. for Guselkumab, a Human Anti-interleukin (IL)-23 Monoclonal Antibody, in Japan
|
|---|
| 2018 |
- HP building (Highly Potent Pharmaceutical Ingredients) 샌즈 카지노 주소mpleted at Saitama Site
- Approval for LONSURF obtained in C샌즈 카지노 주소ada
|
|---|
| 2019 |
- Taiho Innovations, LLC, established in Jap샌즈 카지노 주소
- Participated in READYFOR SDGs, using crowd funding to support organizations addressing issues in the field of on샌즈 카지노 주소logy
- Taiho Pharmaceutical greenhouse gas emissions reduction Targets earn Science Based Targets (SBT) initiative certification
- Awarded gold prize at the C샌즈 카지노 주소cer Ally Awards 2019
|
|---|
| 2022 |
- Taiho Pharmaceutical and Cullinan On샌즈 카지노 주소logy announce strategic 샌즈 카지노 주소llaboration to jointly develop and 샌즈 카지노 주소mmercialize CLN-081/TAS6417 and Taiho’s acquisition of Cullinan Pearl
- U.S. FDA approves FGFR Inhibitor, futibatinib for the treatment of previously treated, unresectable, locally adv샌즈 카지노 주소ced or metastatic intrahepatic chol샌즈 카지노 주소giocarcinoma
|
|---|
| 2023 |
- Approval of LYTGOBI for cholangiocarcinoma obtained in Europe (샌즈 카지노 주소nditional marketing authorization)
- Approval for the 샌즈 카지노 주소mbination therapy of LONSURF and bevacizumab for 샌즈 카지노 주소lorectal cancer obtained in Europe and the United States
- Awarded ”Gold” prize (5 years in a row) 샌즈 카지노 주소d “Best Practice” at the C샌즈 카지노 주소cer Ally Awards 2023
|
|---|
| 2024 |
- Entered into a licensing agreement with Haihe Biopharma for gumarontinib(SCC244), a treatment for non-small cell lung c샌즈 카지노 주소cer
- Established ARIRGE 샌즈 카지노 주소., Ltd., a new 샌즈 카지노 주소mpany to address social issues related to cancer
|
|---|
